NASDAQ · Biotechnology · USD
Mereo BioPharma Group plc (MREO) Stock Analysis
Mereo BioPharma Group plc (MREO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
MREO Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.30
- Previous Close
- $0.30
- Day's Range
- 0.29–0.31
- 52-Week Range
- 0.20–2.37
- Volume
- 329.28K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.14
Valuation
- Market Cap
- $46.50M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.20
Financials (FY)
- Revenue (FY)
- $500.00K
- Net Income (FY)
- −$41.88M
- Shares Outstanding
- 159.69M
- 1-Year Return
- −86.33%
Dividend and dates
- Earnings Date
- November 9, 2026estimated
- Avg Volume
- 4.05M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, MREO closed at $0.29, −86.33% over 1 year.
Mereo BioPharma Group plc (MREO) has a market capitalization of $46.50M.
In fiscal 2025, MREO reported revenue of $500.00K.
MREO Stock Return by Calendar Year
Mereo BioPharma Group plc (MREO) return since Apr 2019: what $10,000 became
- 1 year
- $10,000 $1,367
- −86.33%
- 5 years
- $10,000 $1,342
- −86.58%
- Since Apr 2019
- $10,000 $448
- −95.52%
If you had invested $10,000 in Mereo BioPharma Group plc (MREO) at the close on April 24, 2019, the earliest close on record here, it would have been worth $448 at the close on October 21, 2026: −95.52% in total, −33.93% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −30.17% |
| 2025 | −88.09% |
| 2024 | +51.52% |
| 2023 | +208.00% |
| 2022 | −53.13% |
| 2021 | −55.31% |
| 2020 | +9.15% |
| 2019 (partial year) | −49.54% |
As of October 21, 2026.
MREO Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $500.00K | −$41.88M | −8,375.6% |
| 2024 | $0.00 | −$43.25M | — |
| 2023 | $10.00M | −$29.47M | −294.7% |
| 2022 | $0.00 | −$42.22M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $500.00K | $367.00K | −$38.26M | −$41.88M | −8,375.6% |
| 2024 | $0.00 | $0.00 | −$45.72M | −$43.25M | — |
| 2023 | $10.00M | $7.43M | −$27.14M | −$29.47M | −294.7% |
| 2022 | $0.00 | $1.15M | −$52.70M | −$42.22M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
JP Morgan Downgrades Mereo BioPharma Group to Underweight
BenzingaMereo BioPharma Group Q2 EPS $(0.01), Inline
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B